Pretreatment Brain States Identify Likely Nonresponse to Standard Treatments for Depression

• Authors: Callie L. McGrath, Emory University; Mary Kelley, Emory University; Boadie W Dunlop, Emory University; Paul Holtzheimer, Emory University; Helen S Mayberg, Emory University; W Edward Craighead, Emory University
• Journal Title: Biological Psychiatry
• Volume: Volume 76, Number 7
• Publisher: Elsevier: 12 months | 2014-10-01, Pages 527-535
• Type of Work: Article | Post-print: After Peer Review
• Publisher DOI: http://doi.org/10.1016/j.biopsych.2013.12.005
• Subjects: Biology, Neuroscience; Health Sciences, Mental Health; Biology, Biostatistics
• Keywords: Science & Technology; Life Sciences & Biomedicine; Neurosciences; Psychiatry; Neurosciences & Neurology; Antidepressant medication; biomarker; depression; psychotherapy; subcallosal cingulate; superior temporal sulcus; TREATMENT-RESISTANT DEPRESSION; STAR-ASTERISK-D; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIOR THERAPY; MAJOR DEPRESSION; GLUCOSE-METABOLISM; TREATMENT RESPONSE; CINGULATE; PREDICTORS; DISORDER

Abstract

Background: Treatment approaches for major depressive disorder (MDD) result in approximately one third of patients achieving remission after a first treatment. Added treatment generally improves remission rates, but approximately one third of all patients fail to respond after several treatments (sequential monotherapies or combined treatment). A pretreatment biomarker could help identify these patients. Overactivity of the subcallosal cingulate has been associated with failure of response to treatment in MDD, and it is a potential candidate for such a biomarker. Methods: Investigators enrolled 82 patients with MDD currently not receiving treatment in a two-phase treatment study. Patients underwent a fluorodeoxyglucose positron emission tomography scan. After scanning, patients were randomly assigned to 12 weeks of treatment with either escitalopram or cognitive-behavioral therapy (CBT). Patients not achieving remission after 12 weeks of initial treatment were treated with an additional 12 weeks of escitalopram plus CBT. Subcallosal cingulate metabolism was compared between patients who failed to achieve a response and patients who achieved remission as a result of either phase one or phase two treatment. This analysis was followed by a whole-brain analysis making the same comparison. Results: After two phases of treatment (24 weeks), 36 patients were identified as remitters, 6 patients were responders, and 9 patients were nonresponders. Subcallosal cingulate metabolism was significantly higher in nonresponders than remitters. In the follow-up wholebrain analysis, increased superior temporal sulcus activity was also associated with nonresponse to two treatments. Conclusions: Patients with MDD who fail to achieve remission as a result of CBT or escitalopram, either alone or in combination, have a distinct brain metabolic pattern compared with patients who achieve remission as a result of CBT, escitalopram, or their combination.